Jubilant Pharmova : Sustainability Report 2022-23

Forward and

Onward for

SustainABLE

Lives

SUSTAINABILITY REPORT 2022-23

Table of Content:

GRI 2-22

02. Message from the Chairmen

05. About Our Organisation

10. Report Profile

12. Corporate Governance

18. Key Highlights FY 2022

21. Risks and Opportunities

31. Stakeholder Engagement

1. Materiality Assessment
2. Economic Impact

40. Environmental Impact

54. Social Impact

1

93. Membership in Associations

96. United Nations Global Compact

97. GRI Content Index

111. Assurance Statement

113. List of Abbreviations

116. Methodology of Calculations

Jubilant Pharmova Limited | Sustainability Report 2022-23

Message from the Chairmen| About Our Organisation | Report Profile | Corporate Governance | Key Highlights FY 2022 | Risks & Opportunities | Stakeholder Engagement | Materiality Assessment | Economic Impact | Environmental Impact	2
Social Impact | Membership in Associations | United Nations Global Compact | GRI Content Index | Assurance Statement | List of Abbreviations | Methodology of Calculations

Message from the Chairmen

GRI 2-22

Shyam S. Bhartia

Chairman

Hari S. Bhartia

Co-Chairman

& Managing Director

I am pleased to present Jubilant Pharmova Limited's Sustainability Report for the fiscal year 2023 (FY2023). As a pharmaceutical company, our core purpose is to improve lives through scientific and medical advancements. Our commitment to harnessing the power of science and technology has been instrumental in our holistic growth.

Within this report, we emphasize the sustainability challenges and opportunities encountered during FY 2023. Despite the obstacles faced, our company achieved stable revenues due to the diversification of our businesses. We have expedited capacity expansions to bolster our capabilities and meet evolving demands. Moreover, we have successfully reduced our absolute greenhouse gas (GHG) emissions year after year. This year, we are also fulfilling the reporting requirements of the Business Responsibility and Sustainability Reporting (BRSR) as mandated by SEBI. Our BRSR report is enclosed as a part of our Annual Report for FY2023.

Our commitment to sustainability is evidenced by our remarkable achievements in ESG ratings. We attained an outstanding percentile of 94% in the S&P Global ESG Indices CSA 2022 (DJSI), signifying a substantial increase of 42.50% compared to last year's score. We take pride in attaining a GOLD Sustainability rating in EcoVadis, placing us among the top 8% of global pharmaceutical companies. This achievement underscores our dedication to environmental, social, and governance factors. Additionally, we have received an impressive 'B' score band from CDP for 'Climate Change' and 'Water Security.' The company has moved from the 'B-' band (last year's score) to the esteemed 'B' band, known as the 'Management' band. Furthermore, our leading position in the pharmaceutical sector and fourth position across all sectors in the Asia-Pacific Climate Leaders survey by Nikkei Asia validate our commitment to combatting climate change.

Jubilant Pharmova Limited | Sustainability Report 2022-23

Message from the Chairmen| About Our Organisation | Report Profile | Corporate Governance | Key Highlights FY 2022 | Risks & Opportunities | Stakeholder Engagement | Materiality Assessment | Economic Impact | Environmental Impact	3
Social Impact | Membership in Associations | United Nations Global Compact | GRI Content Index | Assurance Statement | List of Abbreviations | Methodology of Calculations

Message from the Chairmen (Contd.)

GRI 2-22

Our progress towards sustainability goals has been truly remarkable. We have surpassed expectations by achieving a 23.9% reduction in specific energy consumption, a 17.5% decrease in specific water consumption, and an impressive 56.9% reduction in specific greenhouse gas (GHG) emissions compared to our FY 2019 baselines. Additionally, our unwavering dedication and adaptability have resulted in a significant 45% reduction in absolute GHG emissions since FY 2019. We also take equal pride in maintaining a gender diversity ratio of 25.2% and remain focused on further enhancing diversity within our workforce.

This report provides detailed insights into our initiatives, progress, and future plans. We acknowledge the evolving business landscape and the growing demands from stakeholders regarding ESG issues. Our strong ESG position instills confidence among stakeholders and allows us to explore new markets.

ESG excellence is ingrained in our corporate culture and reflected in our policies. We strive to minimize our environmental footprint, uphold good governance, and create shared value. We are integrating our in-house portal, 'Sanchetna,' to record all identified hazards and implement Corrective Action Preventive Action (CAPA) across all our manufacturing sites and offices. We also have 'HumanTech,' a cloud-based software utilizing artificial intelligence technology, to assess ergonomic risks in our manufacturing operations and provide systematic solutions. Additionally, last year our Radiopharmacy business in the United States has implemented a Driver Safety training program called Driver Insights to address specific skill gaps.

Transparency is a core value for us, and we consistently share our ESG performance and goals with stakeholders. Our sustainability culture is fueled by our strong value system, and we continue to innovate and learn from the markets we serve. We aim to inspire the right talent and foster a supportive team that embraces change and supports our organization's cause.

Jubilant Pharmova Limited | Sustainability Report 2022-23

Message from the Chairmen| About Our Organisation | Report Profile | Corporate Governance | Key Highlights FY 2022 | Risks & Opportunities | Stakeholder Engagement | Materiality Assessment | Economic Impact | Environmental Impact	4
Social Impact | Membership in Associations | United Nations Global Compact | GRI Content Index | Assurance Statement | List of Abbreviations | Methodology of Calculations

Message from the Chairmen (Contd.)

GRI 2-22

As we move forward, we are committed to giving back more than we take. We look forward to continued sustainable growth in collaboration with our stakeholders.

For more comprehensive insights into our initiatives and accomplishments,

I invite you to explore the relevant sections of our sustainability report.

We hope you enjoy browsing this report!

Shyam S. Bhartia	Hari S. Bhartia
Chairman	Co-Chairman & Managing Director

Jubilant Pharmova Limited | Sustainability Report 2022-23

Message from the Chairmen | About Our Organisation| Report Profile | Corporate Governance | Key Highlights FY 2022 | Risks & Opportunities | Stakeholder Engagement | Materiality Assessment | Economic Impact | Environmental Impact	5
Social Impact | Membership in Associations | United Nations Global Compact | GRI Content Index | Assurance Statement | List of Abbreviations | Methodology of Calculations
About Our Organisation	GRI 2-1,2-6

Our Businesses

Jubilant Pharmova Limited, is an integrated global Pharmaceuticals Company with three business segments, Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Company has a team of multicultural people across the globe and is committed to delivering value to its customers. The Company is well recognised as a 'Partner of Choice' by leading pharmaceutical companies worldwide.

Proprietary Novel Drugs:

Proprietary Novel Drugs business through Jubilant Therapeutics Inc. is an innovative patient-centric biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders.

Business Segments

Pharmaceuticals:

Pharmaceuticals business through Jubilant Pharma Limited is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 compounding nuclear pharmacies (Radiopharmacies) and three Positron Emission Tomography (PET) drug manufacturing facilities in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables and Non-sterile products, Active Pharmaceutical Ingredients and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India.

Contract Research and Development Services:

Contract Research and Development Services business represented by Jubilant Biosys Limited provides innovation and collaborative research to global pharmaceutical innovators through two world-class research centers in Bengaluru and Noida in India.

Jubilant Pharmova Limited | Sustainability Report 2022-23

Message from the Chairmen | About Our Organisation| Report Profile | Corporate Governance | Key Highlights FY 2022 | Risks & Opportunities | Stakeholder Engagement | Materiality Assessment | Economic Impact | Environmental Impact	6
Social Impact | Membership in Associations | United Nations Global Compact | GRI Content Index | Assurance Statement | List of Abbreviations | Methodology of Calculations

About Our Organisation (Contd.)	GRI 2-1,2-6

Highlights

Radiopharmaceuticals

Second largest Radiopharmaceutical manufacturer in the nuclear medicine industry in the United States.

Second largest centralised commercial Radiopharmacy network in the United States with a national footprint of 46 Radiopharmacies across 22 states.

Allergy Immunotherapy Products

Jubilant Pharma's HollisterStier Allergy, business division, has been a leader in the United States allergy immunotherapy industry for over 100 years.

Currently the sole producer and supplier of venom products for the treatment of allergies in the United States.

Shareholding pattern for Jubilant Pharmova Limited as on 31.3.2023:

Promoter and Promoter Group:

Public:

Active Pharmaceutical Ingredients (APIs)

Leading global suppliers for several Key APIs with prominent presence in markets such as North America, South America, Europe, Japan, Asia Pacific (APAC) and the Middle East.

Solid Dosage Formulations

We are one of the leading formulations player engaged in the development, manufacture, sale, and distribution of proprietary generic pharmaceutical products principally in the United States, and with a growing presence in Europe, Canada, Japan, Australia and the rest of the world.

Jubilant Pharmova Limited | Sustainability Report 2022-23

Message from the Chairmen | About Our Organisation| Report Profile | Corporate Governance | Key Highlights FY 2022 | Risks & Opportunities | Stakeholder Engagement | Materiality Assessment | Economic Impact | Environmental Impact	7
Social Impact | Membership in Associations | United Nations Global Compact | GRI Content Index | Assurance Statement | List of Abbreviations | Methodology of Calculations

About Our Organisation (Contd.)	GRI 2-1

The Company started its journey more than 40 years ago and its Values have been the foundation of its success. Backed by the belief of each employee, every step at Jubilant Pharmova Limited is driven by these set of values.

These values are deeply inculcated in the employees at all levels through regular training and other initiatives.

Jubilant Pharmova Limited | Sustainability Report 2022-23

Message from the Chairmen | About Our Organisation| Report Profile | Corporate Governance | Key Highlights FY 2022 | Risks & Opportunities | Stakeholder Engagement | Materiality Assessment | Economic Impact | Environmental Impact	8
Social Impact | Membership in Associations | United Nations Global Compact | GRI Content Index | Assurance Statement | List of Abbreviations | Methodology of Calculations

About Our Organisation (Contd.)

Our Global Presence GRI 2-1, 2-6

India | USA | Canada | Belgium | China | Singapore | South Africa | United Kingdom | Australia

Salisbury	United	South Africa
Yardley	Kingdom
	Belgium	Noida

Corporate Office

Company Office

3 R&D Facilities

Montreal

Roorkee

China

Spokane

CANADA

USA

INDIA

Nanjangud

Manufacturing Facility

Manufacturing Facility

R&D Facility

Company Office

Corporate Office

Singapore

Australia

Bengaluru

R&D Facility

Company Office

Jubilant Pharmova Limited | Sustainability Report 2022-23

Message from the Chairmen | About Our Organisation| Report Profile | Corporate Governance | Key Highlights FY 2022 | Risks & Opportunities | Stakeholder Engagement | Materiality Assessment | Economic Impact | Environmental Impact	9
Social Impact | Membership in Associations | United Nations Global Compact | GRI Content Index | Assurance Statement | List of Abbreviations | Methodology of Calculations

About Our Organisation (Contd.)

Our Global Presence GRI 2-2, 2-6

Scope of this report: All sites and subsidiaries of the Company as shown in the above map. Further, information from company offices only accounts for headcount numbers.

Location of Headquarters:

Jubilant Pharmova Limited

Plot 1A, Sector 16A, Noida-201301,

Uttar Pradesh, India

Pharmaceuticals

Kirkland, Montreal, Canada

US FDA approved facility for contract manufacturing of Sterile Injectable Kirkland, Montreal, Canada

US FDA approved facility for Radiopharmaceuticals Nanjangud, Karnataka, India US FDA approved Active Pharmaceutical Ingredients (API) facility

Roorkee, Uttarakhand, India Solid Dosage formulation (Tablets & Capsules) facility

Spokane, Washington, USA

US FDA approved facility for contract manufacturing of Sterile Injectable and Allergy Therapy Products

Salisbury, Maryland, USA

US FDA approved facility for Generics (Tablets & Capsules)

Noida, Uttar Pradesh, India

Research Facility (3 units)

Contract Research and Development Services

• Noida, Uttar Pradesh, India Research Facility
• Bengaluru, Karnataka, India Research Facility

Key Subsidiary Companies

Jubilant Pharma Limited

• Jubilant HollisterStier LLC, Spokane, USA
• Jubilant DraxImage Inc., Montreal, Canada
• Jubilant Cadista Pharmaceuticals Inc., Salisbury, USA
• Jubilant DraxImage Radiopharmacies Inc. (JDRI), USA
• Jubilant Pharma Holdings Inc. (JPHI)
• Jubilant Generics Limited, India

Jubilant Biosys Limited, India

Jubilant Therapeutics Inc

Partnerships

Jubilant HollisterStier GP, Montreal, Canada**

**It is a Canada based partnership

managed by two subsidiaries of the Company - Jubilant HollisterStier Inc. and Draxis Pharma LLC.

Please refer to the Company's Annual Report for further

information:

www.jubilantpharmova.com/investors/ financials/annual-reports

Jubilant Pharmova Limited | Sustainability Report 2022-23